Login to Your Account

Anergis Preps for Pivotal Trial of Allergy Vaccine, Seeks Partner

By Nuala Moran
Staff Writer

Wednesday, October 23, 2013

LONDON – Anergis SA released new immunological data from the Phase IIb study of its lead product Allert, proving the synthetic allergy vaccine acts in the same way as traditional desensitizing allergy treatments and providing a comfort factor for potential pharma partners as licensing discussions progress.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription